2026-10-13T00:20:31Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33998558 2026-09-25T17:32:59Z category_4 category_7 category_12 category_13 category_14 category_16 category_21 category_873 category_46 category_734 category_61 category_64 category_132 portal_5 item_type_3 month_year_09_2026

<p>Original data of WB.</p> Kaymin Wu (25111283) Rong Chen (29176) Xin Liu (43569) Youwu He (4233211) Biochemistry Medicine Cell Biology Genetics Molecular Biology Physiology Biotechnology Chemical Sciences not elsewhere classified Immunology Biological Sciences not elsewhere classified Developmental Biology Cancer Infectious Diseases vancouver scar scale transforming growth factor smooth muscle actin several organ systems responsive trend within reduced inflammatory infiltration organized collagen fibers molecular analyses showed ligustrum lucidum </ improved dermal architecture extracellular matrix deposition extracellular matrix accumulation demonstrated antifibrotic activity decreased dermal thickening associated wound remodeling related molecular responses ligustroside may represent animals received ligustroside tested dose range div >< p ligustroside attenuates fibrosis wound formation remodeling phase related signaling related markers β1 expression vehicle control results suggest promising plant profibrotic signaling myofibroblast activation including tgf histopathological staining findings indicate fibroblast activation evaluated using derived candidate 10 mg <div><p>Fibrosis-associated wound remodeling is a feature of cutaneous wound healing characterized by fibroblast activation, extracellular matrix deposition, and profibrotic signaling. Ligustroside, a major iridoid glycoside derived from <i>Ligustrum lucidum</i>, has demonstrated antifibrotic activity in several organ systems, but its effects on cutaneous wound remodeling remain unclear. In this study, a full-thickness excisional wound model was established in female Sprague–Dawley rats to investigate the effects of ligustroside on fibrosis-associated wound remodeling. Animals received ligustroside (5 or 10 mg/kg) or vehicle control. Wound formation was evaluated using the Vancouver Scar Scale, histopathological staining, and analysis of fibrosis-related markers. Ligustroside treatment significantly reduced wound severity during the remodeling phase and improved dermal architecture, as evidenced by decreased dermal thickening, reduced inflammatory infiltration, and more organized collagen fibers. Molecular analyses showed that ligustroside markedly downregulated α-smooth muscle actin and transforming growth factor-β1 expression, accompanied by showing a dose-responsive trend within the tested dose range. These findings indicate that ligustroside attenuates fibrosis-associated wound remodeling and suppresses fibrosis-related molecular responses, including TGF-β1 expression, myofibroblast activation, and extracellular matrix accumulation. Collectively, these results suggest that ligustroside may represent a promising plant-derived candidate for antifibrotic wound modulation.</p></div> 2026-09-25T17:32:49Z Dataset Dataset 10.1371/journal.pone.0358737.s007 https://figshare.com/articles/dataset/_p_Original_data_of_WB_p_/33998558 CC BY 4.0